Gossamer Bio (GOSS) Non-Current Deferred Tax Liability (2018 - 2023)
Gossamer Bio (GOSS) posted quarterly Non-Current Deferred Tax Liability of $565000.0 for Q4 2022, down 95.02% year-over-year from $11.3 million in Q4 2021, and down 95.02% quarter-over-quarter from $11.3 million in Q4 2021.
Gossamer Bio (GOSS) Non-Current Deferred Tax Liability (2018 - 2023) Analysis & Trends
Gossamer Bio's Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $565000.0 for Q4 2022.
- In Q4 2022, Non-Current Deferred Tax Liability fell 95.02% year-over-year to $565000.0; the TTM figure through Dec 2022 stood at $565000.0 (down 95.02% YoY), while the FY2022 annual figure was $565000.0, down 95.02% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2022 stood at $565000.0, down from $11.3 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $13.6 million in Q4 2020, with the low at $16000.0 in Q4 2018.
- The 5-year median for Non-Current Deferred Tax Liability is $565000.0 (2022), against an average of $5.1 million.
- The sharpest annual moves came in 2020 and 2022: Non-Current Deferred Tax Liability jumped 23729.82% in 2020, then slumped 95.02% in 2022.
- Gossamer Bio's Non-Current Deferred Tax Liability stood at $16000.0 in 2018, then jumped by 256.25% to $57000.0 in 2019, then surged by 23729.82% to $13.6 million in 2020, then decreased by 16.55% to $11.3 million in 2021, then plunged by 95.02% to $565000.0 in 2022.
- Business Quant data shows GOSS's Non-Current Deferred Tax Liability at $565000.0 in Q4 2022, $11.3 million in Q4 2021, and $13.6 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 768,000.00 |
| Dec 31, 2023 | 768,000.00 |
| Dec 31, 2022 | 565,000.00 |
| Dec 31, 2022 | 565,000.00 |
| Dec 31, 2021 | 11.34 Mn |
| Dec 31, 2021 | 11.34 Mn |
| Dec 31, 2020 | 13.58 Mn |
| Dec 31, 2020 | 13.58 Mn |
| Dec 31, 2019 | 57,000.00 |
| Dec 31, 2019 | 57,000.00 |
| Dec 31, 2018 | 16,000.00 |
| Dec 31, 2018 | 16,000.00 |